Core Biostatistics

Core D redThe purpose of Biostatistics and Analysis Core is primarily to provide statistical, epidemiologic, health services research and bioinformatics support to CFAR investigators for the development of research proposals including data management and quality control with analyses. This is accomplished by a collaborative team of investigators who provide input on study design and analyses as well as logistical issues and problems impacting the quality and integrity of studies in addition to advice on literature interpretation, assessment of new methodologies and support for studying unique aspects of HIV in the US Deep South. The range of studies include pilot data and phase I clinical trials for drug discovery to pathogenesis, prevention (both primary and secondary) and the "new" natural history of HIV infection in the treatment era. The type of studies include both genetic and non-genetic such as observational designs, clinical research, health services research, health economic modeling and other evaluations such as mixed treatment comparisons, indirect treatment comparisons and causal modeling.


The Biostatistics and Analysis Core serves as the centralized resource to provide access to statistical expertise and data management to support research programs and projects conducted by CFAR members. The value added to the CFAR scientific mission is that the Biostatistics and Analysis Core provides statistical, data management and computing support for a number of purposes: Statistical design of experiments to efficiently address scientific questions; Sample size estimation to assist investigators in determining study feasibility; Data analysis of preliminary data to be used in hypothesis generation; Secondary data analyses of databases; Guidance in structuring databases to ensure that required data to address scientific issues can be easily retrieved and analyzed; Availability of software resources for statistical and data management purposes. Acquisition of some software is costly, but the CFAR Biostatistics and Analysis Core utilizes the software across CFAR members and, in some cases, across other applications, to minimize the cost to the CFAR.


Perry BA, Westfall AO, Molony E, Tucker R, Ritchie C, Saag MS, Mugavero MJ, Merlin JS. Characteristics of an Ambulatory Palliative Care Clinic for HIV-Infected Patients. J Palliat Med. 2013 Mar 11. [Epub ahead of print] PubMed PMID: 23477304.

Willig JH, Westfall AO, Mugavero M, Nevin CR, Correll T, Duggal A, Guyer W, Saag MS, Juday T. Effect of persistency of first-line HIV antiretroviral therapy on clinical outcomes. AIDS Res Hum Retroviruses. 2013 Apr;29(4):698-703. doi:10.1089/AID.2012.0241. Epub 2012 Dec 18. PubMed PMID: 23151191; PubMed Central PMCID: PMC3607971.

Zhang J, Waubant E, Cutter G, Wolinsky JS, Glanzman R. EDSS variability before randomization may limit treatment discovery in primary progressive MS. Mult Scler. 2013 May;19(6):775-81. doi: 10.1177/1352458512459685. Epub 2012 Oct 1. PubMed PMID: 23027880.

Mugavero MJ, Napravnik S, Cole SR, Eron JJ, Lau B, Crane HM, Kitahata MM, Willig JH, Moore RD, Deeks SG, Saag MS, Centers for ARNoICSCS. Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. Clin Infect Dis. 2011;53(9):927-35. PMID: 21890751; PMCID: PMC3189165.

Cole SR, Napravnik S, Mugavero MJ, Lau B, Eron JJ, Jr., Saag MS. Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden. Am J Epidemiol. 2010;171(2):198-205. PMID: 20007202; PMCID: PMC2878100.

Allison DB, Heo M, Flanders DW, Faith MS, Carpenter KM, Williamson DF. Simulation study of the effects of excluding early deaths on risk factor-mortality analyses in the presence of confounding due to occult disease: the example of body mass index. Ann Epidemiol. 1999;9(2):132-42. PMID: 10037558.

Routman JS, Willig JH, Westfall AO, Abroms SR, Varshney M, Adusumilli S, Allison JJ, Savage KG, Saag MS, Mugavero MJ. Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care. Clin Infect Dis. 2010;50(4):574-84. PMID: 20067423; PMCID: PMC2848720.

Cropsey KL, Lane PS, Perkins AC, Clark CB, Hardy S, McCullumsmith C, Stitzer ML. Buprenorphine and medication management in a community corrections population: a pilot study. J Addict Med. 2013;7(3):210-5. PMID: 23609213.

Kim DJ, Westfall AO, Chamot E, Willig AL, Mugavero MJ, Ritchie C, Burkholder GA, Crane HM, Raper JL, Saag MS, Willig JH. Multimorbidity patterns in HIV-infected patients: the role of obesity in chronic disease clustering. J Acquir Immune Defic Syndr. 2012;61(5):600-5. PMID: 23023101; PMCID: PMC3508375.

Burkholder GA, Tamhane AR, Salinas JL, Mugavero MJ, Raper JL, Westfall AO, Saag MS, Willig JH. Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients. Clin Infect Dis. 2012;55(11):1550-7. PMID: 22942209; PMCID: PMC3491860.

Contact Information

Core D.smaller pic                                                    Pictured: Dr. Ashutosh Tamhane, Andy Westfall and Dr. Gary Cutter

Gary Cutter, PhD
Email: cutterg@uab.edu


Eric Chamot, MD, PhD
Email: echamot@uab.edu

Stephen Mennemeyer, PhD
Email: smenneme@uab.edu

Administrative Director

Andy Westfall, MS
Email: AndyW@uab.edu 


Ashutosh Tamhane, MD, PhD
Email: tamhane@uab.edu 

University of Alabama at Birmingham
Ryals Public Health Building
1665 University Boulevard, Room 414
Birmingham AL 35294-0022